Four ErbB targeted anti-cancer agent Geo trip domestic market capture
Peme Trek seed cisplatin extension of PFS 4.2 months compared to, cisplatin Gem Shea turbine ratio 5.4 months extension … tolerance suppression, delay
(No common name Oh party, afatinib) Geo trip non-small cell lung cancer targeted anti-cancer agent of Boehringer Ingelheim △ EGFR (ErbB1) △ HER2 (ErbB2) △ ErbB3 △ ErbB4 4 one of ErbB called ErbB Family, etc. suppression of the target block and the tolerance of the mutant group, to set a strong efficacy of such delay, won the first national approval in the second generation of the target anti-cancer agent.
The company is the 12th, held a geo-trip press conference in Seoul small Oyakehora Westin Chosun Hotel, introduced the major clinical and therapeutic advantages. This medicine last month on the 29th, EGFR (epidermal growth factor receptor) from the Food and Drug destination locally advanced there is a change of activity or metastatic non-small cell lung cancer (NSCLC, NonSmall Cell Lung Cancer) as the primary treatment of patients It was approved. In July and October 2013, it was granted respectively in the US and Europe.
This drug, LUXLung 3 and LUXLung 6 .LUXLung 3 and LUXLung 6 clinical studies demonstrated the efficacy through clinical trials, such as is done in the target the EGFR mutation-positive non-small cell lung cancer patients so far was is the largest registered clinical research programs in the three-phase clinical trials.
Study of LUXLung 3 is, to subject the EGFR mutation non-small cell lung cancer patients 345 people, is a clinical trial comparing the Geo trip administration group and Peme Trek seed (Pemetrexed) cisplatin (cisplatin) administered in combination group. Progression-free survival results Geo trip administered group of study (PFS, progressivefree survial) in 11.1 months, it showed improved results from 6.9 months in the control group.
Targeting 346 patients with EGFR mutation-positive lung cancer study that was done of LUXLung 6, a clinical trial comparing the Geo trip administration group and cisplatin Gem Shea turbine combined administration group. Result progression-free survival of Geo trip administered group of research it was found that was extended than the 5.6 months of chemotherapy group at 11 months.
Dark Van knee Kirk Korea Boehringer Ingelheim president Boehringer Ingelheim, cardiovascular disease, respiratory disease, based on the technology that has been cultivated in the diabetes market, was supposed to be geo-trip in the field of anti-cancer agents and then he said, to show off the innovative treatment necessary at the beginning and cancer patients the next generation of non-small cell lung cancer targeted anti-cancer agents Geo trip .
Bakugunchiru Samsung Seoul hospital blood tumor internal medicine professor who participated as speakers of the day announced the development situation and treatment overview of lung cancer, 7-80’s lung cancer, was four to five months only and not live disease after diagnosis was, but whether discovery and using the targeted anti-cancer agent is a greatly improve the survival rate, the future treatment of lung cancer biomarkers (biomarker) is, without resistance a long period of time can be used to target anti-cancer agent has he said important it .
Then because he has some therapeutic agents while coexist in the market, while representing the meaning must give the various alternative patient, it came out new drugs when viewed from the patient standpoint and just, existing therapeutic agent is defined as not bleeding on the market weave patients see the effect as rather existing therapeutic drugs, he said wonder are also patients with new drug hear well.
Jo Byung-chul Yonsei Severance Hospital Medical Oncology Professor, announced the Geo trip of the main results of clinical research, Geo trip, targets such as the idealized player who won the gold medal in this Sochi Winter Olympics speed skating an anti-cancer agent, Iressa, the first generation of therapeutic agents such as Tarceva by suppressing alone EGFR, lung cancer growth and other organ metastases, Geo trip four ErbB mutations that showed the limits of such survival rate It said that he has a strong anti-cancer force to block the group.
Subsequently, a large LUXLung 3 results of the comparison of chemotherapy and geo trip commonly used to EGFR mutation patients with clinical, Geo trip administration group, for about one year (11.1 months), tumor growth is set to showed promising results have not, side effects were diarrhea, said adjustable level about skin rashes.
Cancer Min Ju Boehringer Ingelheim Medicine director Geo trip is different from the existing therapeutic agents, tumor cell growth, metastasis, continuously and extensively blocking the ErbB Family receptors are important paths that help metabolism as The risk of resistance is greatly reduced, he said next-generation non-small cell lung cancer targeting anti-cancer agent obtained by delaying the time the resistance appears.
Geo trip, such as the first generation drugs existing who received approved primary therapeutic indications of the patient’s condition which is not yet Gupuyofa.
Boehringer Ingelheim official, said, expected to receive the insurance benefits of the primary therapeutic agent to Health Insurance Review Agency and the Ministry of Health and Welfare in out fast.
Professor Cho also that it has received permission as the primary drug is true that many patients that have not been yet insurance coverage can not be benefited situation was not seen an effect as one generation of therapeutic agent as Geo trip is spread to the patient, the government said hope Dopugiru.
Doahyonmin reporter salsajoseilbo